Corcept Therapeutics Advances Pipeline Fueling Growth With Controlled Risk

Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the 11 Best Long Term Low Risk Stocks to Invest in.

The company completes a key drug study and has submitted a new drug application to the U.S. FDA.

Corcept Therapeutics Advances Pipeline Fueling Growth With Controlled Risk

A biologist in a lab coat studying a culture of cells to find a cure for metabolic disorders.

Corcept Therapeutics Incorporated (NASDAQ:CORT) is a California-based company specializing in cortisol modulation through glucocorticoid receptor antagonists. The company’s flagship drug, Korlym®, treats Cushing’s syndrome and features a growing pipeline of over 30 clinical-stage compounds targeting endocrinology, oncology, metabolism, and neurology.

Corcept Therapeutics Incorporated (NASDAQ:CORT) announced the completion of its Phase 1 study involving the examination of the effects of itraconazole on the pharmacokinetics and safety of dazucorilant in healthy adults. The trial involved single-dose dazucorilant and repeated itraconazole doses. The study ran from May 31, 2024, to June 29, 2025, and is now concluded. The findings are expected to optimize drug interaction safety.

Additionally, after gaining positive results from the Phase 3 ROSELLA trial and earlier Phase 2 studies, Corcept Therapeutics Incorporated (NASDAQ:CORT) has submitted a new drug application to the U.S. FDA for relacorilant. The data from the earlier studies indicated that relacorilant combined with nab-paclitaxel highly improves progression-free and overall survival compared to nab-paclitaxel alone.

Analysts, including Piper Sandler and H.C. Wainwright, are maintaining their Buy rating on the stock, with a price target of $131 and $145, respectively.

In addition to the rating, Corcept Therapeutics Incorporated (NASDAQ:CORT) increases its appeal by offering a rare low-risk, high-growth appeal, with a beta of 0.20 and projected EPS growth of 69.48%.

While we acknowledge the risk and potential of CORT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than CORT and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Metal Stocks with Insider Buying in 2025 and 10 Energy Stocks with Insider Buying in 2025

Disclosure. None.